TNFRSF17 and Miyoshi myopathy: Two CAR-T cells products, directed against the Anti-B-cell maturation antigen (BCMA), idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have recently received FDA approval for relapsed/refractory MM in patients who had already underwent four or more prior lines of therapy.